CD19 and acute lymphoblastic leukemia: Efficacy of the γδ T cell-mediated ADCC against CD19+ acute lymphoblastic leukemia was demonstrated using a CD19 antibody (94), as well as a so-called “triplebody” with 2 binding sites for CD19 and 1 for CD16 (95).